Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FeRx begins magnetic drug-delivery trial:

This article was originally published in Clinica

Executive Summary

FeRx has begun a clinical trial to investigate the use of its magnetic targeted carrier (MTC) drug-delivery technology for the treatment of metastatic liver cancer. The trial of the company's MTC-DOX product will assess the MTC microparticles as a means of delivering a widely-used anti-cancer drug, doxorubicin. MTC-DOX is already being tested in clinical trials of patients with primary liver cancers, says the San Diego, California company. MTC microparticles are composed of elemental iron and activated carbon and can be directed to specific sites in the body using an externally applied magnetic field.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT070161

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel